Trade

with

StemCells Inc
(NASDAQ: STEM)
AdChoices
1.17
+0.01
+0.86%
After Hours :
-
-
-

Open

1.17

Previous Close

1.16

Volume (Avg)

343.28k (732.84k)

Day's Range

1.17-1.18

52Wk Range

1.02-2.43

Market Cap.

79.62M

Dividend Rate ( Yield )

-

Beta

1.64

Shares Outstanding

68.64M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 1.20M

    • Net Income

    • -26.44M

    • Market Cap.

    • 79.62M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -2,779.98

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.64

    • Forward P/E

    • -1.86

    • Price/Sales

    • 49.26

    • Price/Book Value

    • -31.35

    • Price/Cash flow

    • -2.26

      • EBITDA

      • -24.21M

      • Return on Capital %

      • -108.60

      • Return on Equity %

      • -1,090.59

      • Return on Assets %

      • -108.60

      • Book Value/Share

      • -0.04

      • Shares Outstanding

      • 68.64M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 5.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.64

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -14.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 39.02

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 72.31

            • 82.75

            • Pre-Tax Margin

            • -2,779.98

            • 39.38

            • Net Profit Margin

            • -2,779.98

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 79.70

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -2,103.70

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 2.28

              • 2.92

              • Quick Ratio

              • 2.18

              • 2.35

              • Interest Coverage

              • -21.78

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -0.04

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.82

                • 277.78

                • P/E Ratio 5-Year High

                • -24.24

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.90

                • 124.82

                • Price/Sales Ratio

                • 50.51

                • 9.35

                • Price/Book Value

                • -32.15

                • 8.50

                • Price/Cash Flow Ratio

                • -2.26

                • 50.25

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -1,090.59

                        (-157.90)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -108.60

                        (-74.70)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -208.73

                        (-142.90)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • -

                      • 1.48

                      • Asset Turnover

                      • 0.04

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -28.61M
                      Operating Margin
                      -2,377.31
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -2.26
                      Ownership

                      Institutional Ownership

                      25.31%

                      Top 10 Institutions

                      29.32%

                      Mutual Fund Ownership

                      3.23%

                      Float

                      98.40%

                      5% / Insider Ownership

                      5.35%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vanguard Total Stock Mkt Idx

                      •  

                        968,924

                      • 0.00

                      • 1.41

                      • Vanguard Extended Market Index Fund

                      •  

                        538,913

                      • 10.11

                      • 0.79

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        234,471

                      • 41.55

                      • 0.34

                      • iShares Micro-Cap

                      •  

                        174,458

                      • 0.84

                      • 0.24

                      • EB DL Non-SL Market Completion Fund

                      •  

                        85,953

                      • 300.36

                      • 0.15

                      • Fidelity Spartan® Total Market Idx Fund

                      •  

                        41,468

                      • 0.00

                      • 0.06

                      • Vanguard Instl Total Stock Market Index

                      •  

                        27,652

                      • 0.00

                      • 0.04

                      • Mellon Cap Market Completion Strategy

                      •  

                        24,203

                      • 935.64

                      • 0.04

                      • Master Extended Market Index Series

                      •  

                        19,530

                      • 0.00

                      • 0.03

                      • USAA Extended Market Index Fund

                      •  

                        19,522

                      • -0.04

                      • 0.03

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • BlackRock Fund Advisors

                      •  

                        2,896,788

                      • +3.61%

                      • 5.08

                      • Vanguard Group, Inc.

                      •  

                        1,006,487

                      • +3.92%

                      • 1.77

                      • Bourgeon Capital Management LLC

                      •  

                        272,102

                      • +20.35%

                      • 0.48

                      • Perceptive Advisors LLC

                      •  

                        271,600

                      • 0.00%

                      • 0.48

                      • Geode Capital Management, LLC

                      •  

                        209,025

                      • 0.00%

                      • 0.37

                      • JANE STREET GROUP, LLC

                      •  

                        133,581

                      • +145.97%

                      • 0.23

                      • BNY Mellon Asset Management Ltd.

                      •  

                        113,301

                      • +209.68%

                      • 0.20

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Slow Growth

                      Style

                      Small Core

                      StemCells, Inc. is a Delaware Corporation incorporated in 1988. The Company is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry. It is f...moreocused on cellular medicine, or the use of stem and progenitor cells as the basis for novel therapeutics and therapies, and enabling technologies for stem cell research, or the use of cells and related technologies to enable stem cell-based research and drug discovery and development. The Company’s primary research and development efforts are focused on cellular medicine, where it seeks to identify and develop stem and progenitor cells as potential therapeutic agents. It currently has two therapeutic product development programs; its CNS Program, which is developing appl...moreications for HuCNS-SC cells, its proprietary human neural stem cell product candidate, and its Liver Program, which is developing applications for its proprietary human liver engrafting cells. It currently markets various proprietary cell culture products under the SC Proven brand, including iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27. The Company’s primary strategy is to identify multiple types of human stem and progenitor cells with therapeutic and commercial importance, to develop techniques and processes to purify these cells for direct transplant and to expand and bank these cells, to advance these cells into clinical development and ultimately, to commercialize them as cell-based therapeutic products. The Company’s research and development activities and the future manufacturing and marketing of its potential therapeutic products are, and would continue to be, subject to regulation for safety and efficacy by numerous governmental authorities in the United States and other countries.lessless

                      Key People

                      Martin M. Mcglynn

                      CEO/CEO, Subsidiary/Director/President/President, Subsidiary

                      Dr. John J. Schwartz,PhD

                      Chairman of the Board/Director

                      Mr. Gregory T. Schiffman

                      CFO/Executive VP, Divisional

                      Dr. Ann Tsukamoto,PhD

                      Executive VP, Divisional

                      Dr. Nicki Vasquez

                      Vice President, Divisional

                      • StemCells Inc

                      • 7707 Gateway Boulevard

                      • Newark, CA 94560

                      • USA.Map

                      • Phone: +1 510 456-4000

                      • Fax: +1 510 456-4001

                      • stemcellsinc.com

                      Incorporated

                      1988

                      Employees

                      58

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: